Thera-SAbDab

RELATLIMAB

> Structural Summary

Therapeutic	Relatlimab
Target	LAG3
Heavy Chain	QVQLQQWGAGLLKPSETLSLTCAVYGGSFSDYYWNWIRQPPGKGLEWIGEINHRGSTNSNPSLKSRVTLSLDTSKNQFSLKLRSVTAADTAVYYCAFGYSDYEYNWFDPWGQGTLVTVSS
Light Chain	EIVLTQSPATLSLSPGERATLSCRASQSISSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGQGTNLEIK
100% seqID Fv Structure	None
99% seqID Fv Structure	None
95-98% seqID Fv Structure	None

There are currently no PDB structures close in sequence to this therapeutic Fv. Click here to build a model with ABodyBuilder.

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder
Test for possible therapeutic developability issues with TAP
Assign canonical forms by sequence with SCALOP
Number the sequences in any numbering scheme with ANARCI: [heavy] [light]

Format	Whole mAb
Isotype	G4
Highest Clinical Trial (June '19)	Phase-II/III
Estimated Status (June '19)	Active
Recorded Developmental Technology	na
INN Year Proposed	2018
INN Year Recommended	2019
Companies Involved	Bristol-Myers Squibb, Ono Pharmaceutical, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Conditions Approved	na
Conditions Active	Malignant melanoma, Colorectal cancer, Gastric cancer, Renal cell carcinoma, Solid tumours, Oesophageal cancer, Glioblastoma
Conditions Discontinued	Chronic lymphocytic leukaemia, Diffuse large B cell lymphoma, Hodgkin's disease, Mantle-cell lymphoma, Non-Hodgkin's lymphoma
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]